Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 352,433,792
  • Shares Outstanding, K 2,693,830
  • Annual Sales, $ 71,890 M
  • Annual Income, $ 16,540 M
  • 36-Month Beta 0.78
  • Price/Sales 4.91
  • Price/Cash Flow 15.82
  • Price/Book 5.05

Price Performance

See More
Period Period Low Period High Performance
1-Month
129.57 +0.97%
on 07/27/17
137.08 -4.56%
on 07/20/17
-4.18 (-3.10%)
since 06/27/17
3-Month
122.34 +6.94%
on 05/11/17
137.08 -4.56%
on 07/20/17
+7.09 (+5.73%)
since 04/27/17
52-Week
109.32 +19.68%
on 12/07/16
137.08 -4.56%
on 07/20/17
+6.06 (+4.86%)
since 07/27/16

Most Recent Stories

More News
Next Support Level for Johnson&Johnson (JNJ) is $129.82

Shares of Johnson&Johnson (NYSE:JNJ) have bearishly opened below the pivot of $131.31 today and have reached the first support level of $130.39. Analysts will be watching for a cross of the next downside...

JNJ : 130.83 (-0.09%)
Proteros Enters into New Research Collaboration with Johnson & Johnson Innovation on Sub-Class of Epigenetic Targets

Proteros biostructures GmbH announced today that the company has entered into a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson,...

JNJ : 130.83 (-0.09%)
Is a Beat in the Cards for Pfizer (PFE) in Q2 Earnings?

While Pfizer, Inc.'s (PFE) new drugs like Ibrance and acquisitions like Hospira are likely to drive sales in Q2, genericization of key drugs, pricing pressure and rising competition will hurt sales.

CELG : 134.15 (-2.61%)
NVO : 41.49 (-1.19%)
JNJ : 130.83 (-0.09%)
PFE : 33.00 (+0.33%)
Biotech Stocks Jul27 Q2 Earnings Roster: BMY, CELG & ALXN

Bristol-Myers Squibb Company (BMY), Celgene (CELG) and Alexion Pharma (ALXN) are set to report second-quarter results on Jul 27.

CELG : 134.15 (-2.61%)
JNJ : 130.83 (-0.09%)
MRK : 63.69 (+3.06%)
NVS : 84.97 (+0.14%)
BMY : 54.24 (-3.11%)
ALXN : 133.92 (+2.17%)
BIIB : 287.95 (-2.59%)
Report: More than 15,000 Adverse Events Linked to Xarelto in 2016

As the number of lawsuits against the blood thinner Xarelto continues to climb, so do reports of injuries and deaths caused by the controversial anticoagulant, according to a recent study by the Institute...

BAYRY : 125.9200 (-3.56%)
JNJ : 130.83 (-0.09%)
Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up

Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.

JNJ : 130.83 (-0.09%)
ABBV : 71.73 (-1.18%)
AMGN : 172.15 (-2.13%)
BIIB : 287.95 (-2.59%)
Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK

We have three pharma giants that are set to report second-quarter results on Jul 26. Let's see how things are shaping up for this quarter.

JNJ : 130.83 (-0.09%)
LLY : 83.02 (+1.44%)
VRTX : 156.19 (-4.42%)
NVS : 84.97 (+0.14%)
GILD : 74.96 (+1.04%)
GSK : 40.75 (-0.24%)
BIIB : 287.95 (-2.59%)
What's in the Cards for Geron (GERN) this Earnings Season?

Investors will be looking at Geron's progress with its hematologic myeloid malignancies pipeline candidate, Imetelstat.

JNJ : 130.83 (-0.09%)
VRTX : 156.19 (-4.42%)
ARNA : 23.33 (-4.27%)
GERN : 2.84 (-3.07%)
Stock Market News for July 25, 2017

Benchmarks turned in mixed performances on Monday.

NFLX : 182.68 (-3.38%)
HIBB : 15.75 (+7.51%)
GOOGL : 952.51 (-1.33%)
AAPL : 150.56 (-1.89%)
JNJ : 130.83 (-0.09%)
MRK : 63.69 (+3.06%)
CLB : 98.48 (-0.33%)
FB : 170.44 (+2.92%)
AMZN : 1,046.00 (-0.65%)
Dermatological Drugs Market Forecast 2017-2027

LONDON, July 25, 2017 /PRNewswire/ --

JNJ : 130.83 (-0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Support & Resistance

2nd Resistance Point 132.10
1st Resistance Point 131.46
Last Price 130.83
1st Support Level 129.88
2nd Support Level 128.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.